Literature DB >> 25792238

Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells.

Michiko Hori1, Yuka Kinoshita1, Manabu Taguchi1, Seiji Fukumoto2.   

Abstract

Fibroblast growth factor 23 (FGF23) has been shown to work as a phosphotropic hormone. Although FGF23 reduces the serum phosphate level, it has not been established that phosphate directly regulates FGF23 production. In this study, we investigated whether phosphate can enhance Fgf23 expression using the rat osteoblastic cell line UMR-106, which has been shown to express Fgf23 in response to 1,25-dihydroxyvitamin D [1,25(OH)2D]. Phosphate increased Fgf23 expression in a dose- and time-dependent manner in the presence of 1,25(OH)2D. Phosphate also increased Fgf23 promoter activity, but showed no effect on the half-life of Fgf23 messenger RNA. Phosphonoformic acid and PD98059, an inhibitor of MEK, inhibited the effects of phosphate on Fgf23 expression and promoter activity. In addition, phosphate enhanced production of reactive oxygen species (ROS) in UMR-106 cells, and hydrogen peroxide enhanced FGF23 production in a dose- and time-dependent manner. Hydrogen peroxide also enhanced Elk1 reporter activity, a target of the MEK-extracellular-signal-regulated kinase (ERK) pathway. Furthermore, the effect of phosphate on ROS production and Fgf23 expression was inhibited by apocynin, an inhibitor of NADPH oxidase. These results indicate that phosphate directly enhances Fgf23 transcription without affecting the stability of Fgf23 messenger RNA by stimulating NADPH-induced ROS production and the MEK-ERK pathway in UMR-106 cells.

Entities:  

Keywords:  1,25-Dihydroxyvitamin D; Extracellular-signal-regulated kinase; Fibroblast growth factor 23; Phosphate; Reactive oxygen species

Mesh:

Substances:

Year:  2015        PMID: 25792238     DOI: 10.1007/s00774-015-0651-9

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  21 in total

1.  Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression.

Authors:  Q J Li; S Vaingankar; F M Sladek; M Martins-Green
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

Authors:  Serge L Ferrari; Jean-Philippe Bonjour; René Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation.

Authors:  Takaaki Okamoto; Manabu Taguchi; Tomoko Osaki; Seiji Fukumoto; Toshiro Fujita
Journal:  J Bone Miner Metab       Date:  2013-09-20       Impact factor: 2.626

Review 4.  Fibroblast growth factor 23 as a phosphotropic hormone and beyond.

Authors:  Seiji Fukumoto; Yuichiro Shimizu
Journal:  J Bone Miner Metab       Date:  2011-08-06       Impact factor: 2.626

5.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

Authors:  Shiguang Liu; Wen Tang; Jianping Zhou; Jason R Stubbs; Qiang Luo; Min Pi; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

6.  Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.

Authors:  Hitoshi Saito; Akira Maeda; Shu-Ichi Ohtomo; Michinori Hirata; Kenichiro Kusano; Shigeaki Kato; Etsuro Ogata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2004-11-05       Impact factor: 5.157

7.  Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Authors:  Takashi Shigematsu; Junichiro James Kazama; Takeyoshi Yamashita; Seiji Fukumoto; Tatsuo Hosoya; Fumitake Gejyo; Masafumi Fukagawa
Journal:  Am J Kidney Dis       Date:  2004-08       Impact factor: 8.860

8.  Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans.

Authors:  Nobuaki Ito; Seiji Fukumoto; Yasuhiro Takeuchi; Shu Takeda; Hisanori Suzuki; Takeyoshi Yamashita; Toshiro Fujita
Journal:  J Bone Miner Metab       Date:  2007-10-25       Impact factor: 2.626

Review 9.  Bone as an endocrine organ.

Authors:  Seiji Fukumoto; T John Martin
Journal:  Trends Endocrinol Metab       Date:  2009-06-21       Impact factor: 12.015

10.  Effects of arsenic on modification of promyelocytic leukemia (PML): PML responds to low levels of arsenite.

Authors:  Seishiro Hirano; Takayuki Watanabe; Yayoi Kobayashi
Journal:  Toxicol Appl Pharmacol       Date:  2013-10-14       Impact factor: 4.219

View more
  18 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

3.  Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients.

Authors:  Yuichi Takashi; Shu Wakino; Hitoshi Minakuchi; Masashi Ishizu; Akio Kuroda; Hisato Shima; Manabu Tashiro; Keiko Miya; Kazuyoshi Okada; Jun Minakuchi; Shu Kawashima; Munehide Matsuhisa; Toshio Matsumoto; Seiji Fukumoto
Journal:  J Bone Miner Metab       Date:  2019-08-16       Impact factor: 2.626

4.  A G protein-coupled, IP3/protein kinase C pathway controlling the synthesis of phosphaturic hormone FGF23.

Authors:  Qing He; Lauren T Shumate; Julia Matthias; Cumhur Aydin; Marc N Wein; Jordan M Spatz; Regina Goetz; Moosa Mohammadi; Antonius Plagge; Paola Divieti Pajevic; Murat Bastepe
Journal:  JCI Insight       Date:  2019-09-05

Review 5.  How do we sense phosphate to regulate serum phosphate level?

Authors:  Seiji Fukumoto; Yuichi Takashi; Maria K Tsoumpra; Shun Sawatsubashi; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2019-12-03       Impact factor: 2.626

Review 6.  Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder.

Authors:  Kenichi Akiyama; Takaaki Kimura; Kazuhiro Shiizaki
Journal:  Int J Endocrinol       Date:  2018-03-27       Impact factor: 3.257

7.  Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation.

Authors:  Yuichi Takashi; Hidetaka Kosako; Shun Sawatsubashi; Yuka Kinoshita; Nobuaki Ito; Maria K Tsoumpra; Masaomi Nangaku; Masahiro Abe; Munehide Matsuhisa; Shigeaki Kato; Toshio Matsumoto; Seiji Fukumoto
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-16       Impact factor: 11.205

Review 8.  FGF23 and its role in X-linked hypophosphatemia-related morbidity.

Authors:  Signe Sparre Beck-Nielsen; Zulf Mughal; Dieter Haffner; Ola Nilsson; Elena Levtchenko; Gema Ariceta; Carmen de Lucas Collantes; Dirk Schnabel; Ravi Jandhyala; Outi Mäkitie
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

Review 9.  The Molecular Basis of Calcium and Phosphorus Inherited Metabolic Disorders.

Authors:  Anna Papadopoulou; Evangelia Bountouvi; Fotini-Eleni Karachaliou
Journal:  Genes (Basel)       Date:  2021-05-13       Impact factor: 4.096

10.  Clinical and Genetic Characteristics of 153 Chinese Patients With X-Linked Hypophosphatemia.

Authors:  Xiaoyun Lin; Shanshan Li; Zhenlin Zhang; Hua Yue
Journal:  Front Cell Dev Biol       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.